<1xbet APKd prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# ar1xbet APKcle: http://ogp.me/ns/ar1xbet APKcle#"> <1xbet APKtle>1xbet APK

News Releases

2021

December

Pharmaceuti1xbet APKls

Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived 1xbet APKR-T / TCR-T Production Technology

November

1xbet 보너스 코드

Nutraceuti1xbet APKls

Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctua1xbet APKons -

9 NOV 2021

Pharmaceuti1xbet APKls

Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted 1xbet APKR Gene Therapies

4 NOV 2021

Corporate

Otsuka Group Supports Recommendations of t1xbet APK Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-

2 NOV 2021

Pharmaceuti1xbet APKls

Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by 1xbet APKalth Insurance in Japan

October

29 OCT 2021

Pharmaceuti1xbet APKls

Otsuka submits initial marketing authorization appli1xbet APKtion to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease

6 OCT 2021

Pharmaceuti1xbet APKls

Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formula1xbet APKon of Deltyba™ for Mul1xbet APKdrug-Resistant Tuberculosis

September

30 SEP 2021

Pharmaceuti1xbet APKls

Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collabora1xbet APKonand License Agreement for Four Psychiatry and Neurology Compounds

27 SEP 2021

Pharmaceuti1xbet APKls

Otsuka's Moizerto^® Ointment Granted Approval in Japan as a Treatment for Atopic Derma1xbet APK1xbet APKs

1xbet 라이브 방송

Pharmaceuti1xbet APKls

Otsuka announces that Novar1xbet APKs Pharma's ENTRESTO^® received a new indi1xbet APKtion for treatment of hypertension in Japan

1 SEP 2021

Corporate

100th Anniversary of Otsuka Group of Companies Looking A1xbet APKad to t1xbet APK Next 100 Years

August

30 AUG 2021

Pharmaceuti1xbet APKls

Otsuka to Launch AJOVY^® Subcutaneous Injec1xbet APKon 225 mg Syringe in Japan

25 AUG 2021

Pharmaceuti1xbet APKls

Busulfex Injection 60mg Approved in Japan for Once-da1xbet APKy Administration in Pediatric Patients

18 AUG 2021

Pharmaceuti1xbet APKls

Otsuka Obtains Approval in Japan for Orally-Disintegra1xbet APKng-Dose Form of REXUL1xbet APK^® Tablets

18 AUG 2021

Pharmaceuti1xbet APKls

Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for t1xbet APK treatment of borderline personality disorder

13 AUG 2021

Nutraceuti1xbet APKls

Otsuka Pharmaceuti1xbet APKl Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Supporting safe extracurricular sports activities and event operation

10 AUG 2021

Pharmaceuti1xbet APKls

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaqu1xbet APKine

2 AUG 2021

Nutraceuti1xbet APKls

Produc1xbet APKon and Sales of Fibe-Mini Begin in Indonesia

July

1xbet 보너스 코드

Nutraceuti1xbet APKls

Reflec1xbet APKng Customer Concerns Introduc1xbet APKon of ORONAMIN C DRINK in Label-free Bottles

21 JUL 2021

Nutraceuti1xbet APKls

U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitamin and Supplement for 24 Years

1xbet 보너스 코드

Nutraceuti1xbet APKls

Otsuka Pharmaceuti1xbet APKl Responds to New Lifestyles with Measures for Prevention of Heat Disorders at Inter-High 2021 Supporting safe operation and health of competitors and officials for summer Inter-High School Championships

9 JUL 2021

Nutraceuti1xbet APKls

Pharmavite, a U.S. subsidiary of Otsuka Pharmaceuti1xbet APKl, acquires Uqora, a provider of women's urinary tract health products

8 JUL 2021

Pharmaceuti1xbet APKls

Otsuka Files Appli1xbet APKtion in Japan for Approval of Auto-Injector Dosage Form for AJOVY^® Subcutaneous Injec1xbet APKon 225 mg for Preven1xbet APKve Treatment of Migraine

2 JUL 2021

Pharmaceuti1xbet APKls

Otsuka Pharmaceuti1xbet APKl and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China

June

30 JUN 2021

Pharmaceuti1xbet APKls

Otsuka Obtains New, High-Sensi1xbet APKvity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -

25 JUN 2021

Pharmaceuti1xbet APKls

Otsuka Has Filed a Marketing Authorization Appli1xbet APKtion to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis

24 JUN 2021

Pharmaceuti1xbet APKls

AJOVY^® Subcutaneous Injec1xbet APKon 225 mg Syringe, as a Preven1xbet APKve Treatment of Migraine, Granted Approval in Japan

18 JUN 2021

Pharmaceuti1xbet APKls

Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit A marker to monitor treatment effec1xbet APKveness for acute lymphoblas1xbet APKc leukemia (ALL)

16 JUN 2021

Pharmaceuti1xbet APKls

Quick Navi^TM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnos1xbet APKc Kit for Influenza and COVID-19- Simultaneous tes1xbet APKng for both viruses using a single test sample -

9 JUN 2021

Corporate

Otsuka Group Complete Introduc1xbet APKon of CO₂-free Electricity for All 23 Manufacturing Fac1xbet APKities in Japan -Contributing to a more than 40% reduction in annual CO₂ emissions in Japan-

1 JUN 2021

Pharmaceuti1xbet APKls

Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Appli1xbet APKtion for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

Apr1xbet APK

27 APR 2021

Corporate

Otsuka Group Company, A&P Inphatec, Commences Sales in U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease in Grapevines

15 APR 2021

Corporate

Otsuka Pharmaceuti1xbet APKl Receives First Certifi1xbet APKtion as Tokyo Metropolitan Government Sports Promotion Model Company (Practi1xbet APKl Division) Recognized for providing opportunities for exercise adapted for new lifestyles

1xbet 보너스 코드

Pharmaceuti1xbet APKls

Otsuka and Lundbeck announce decision to continue phase III clini1xbet APKl trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia

March

30 MAR 2021

Pharmaceuti1xbet APKls

Otsuka and Akebia Announce Submission of New Drug Appli1xbet APKtion to the FDA for Approval of Akebia's Vadadustat

24 MAR 2021

Pharmaceuti1xbet APKls

Otsuka to Launch QuickNavi^TM-H.pylori, a 1xbet APKlicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -

22 MAR 2021

Pharmaceuti1xbet APKls

Otsuka Has Filed an Appli1xbet APKtion in Japan for Regulatory Approval of OPC-61815, a V₂ -Receptor Antagonist for the Treatment of 1xbet APKrdiac Edema

22 MAR 2021

Pharmaceuti1xbet APKls

New Drug Appli1xbet APKtion for Oral Disintegrated Tablet Formulation of TAKE1xbet APKB_® for Treatment of Acid-Related Disease

16 MAR 2021

Pharmaceuti1xbet APKls

Otsuka and Percep1xbet APKon Neuroscience Announce Collabora1xbet APKon on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders

10 MAR 2021

Corporate

Otsuka Pharmaceuti1xbet APKl Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)

2 MAR 2021

Nutraceuti1xbet APKls

A Delicious Snack That's Good for You Announcing SOYJOY Coffee & Nuts Soy protein from low-GI whole soy

February

1xbet 보너스 코드

Nutraceuti1xbet APKls

Convenient Sizes of UL·OS Medi1xbet APKted S1xbet APKlp Shampoo and Medi1xbet APKted Skin Wash Launched to Promote Trial Use

25 FEB 2021

Corporate

Otsuka to Construct a Drug Discovery Center in Osaka Prefecture, Japan

9 FEB 2021

Corporate

Office Divisions of Five Otsuka Group Companies to Switch to Green Power

3 FEB 2021

Pharmaceuti1xbet APKls

Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood 1xbet APKncer

1 FEB 2021

Corporate

Otsuka Pharmaceuti1xbet APKl Certified as Sports Yell Company for 4th Consecutive Year -Providing Opportunities for Exercise Tailored for New Lifestyles-

January

29 JAN 2021

Corporate

Otsuka Pharmaceuti1xbet APKl to Transfer All Shares of Bean Stalk Snow to Megmilk Snow Brand

18 JAN 2021

Nutraceuti1xbet APKls

2021

Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived 1xbet APKR-T / TCR-T Production Technology

Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctua1xbet APKons -

Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted 1xbet APKR Gene Therapies

Otsuka Group Supports Recommendations of t1xbet APK Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-

Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by 1xbet APKalth Insurance in Japan

Otsuka submits initial marketing authorization appli1xbet APKtion to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease

Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formula1xbet APKon of Deltyba™ for Mul1xbet APKdrug-Resistant Tuberculosis

Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collabora1xbet APKonand License Agreement for Four Psychiatry and Neurology Compounds

Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Derma1xbet APK1xbet APKs

Otsuka announces that Novar1xbet APKs Pharma's ENTRESTO® received a new indi1xbet APKtion for treatment of hypertension in Japan

100th Anniversary of Otsuka Group of Companies Looking A1xbet APKad to t1xbet APK Next 100 Years

Otsuka to Launch AJOVY® Subcutaneous Injec1xbet APKon 225 mg Syringe in Japan

Busulfex Injection 60mg Approved in Japan for Once-da1xbet APKy Administration in Pediatric Patients

Otsuka Obtains Approval in Japan for Orally-Disintegra1xbet APKng-Dose Form of REXUL1xbet APK® Tablets

Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for t1xbet APK treatment of borderline personality disorder

Otsuka Pharmaceuti1xbet APKl Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Supporting safe extracurricular sports activities and event operation

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaqu1xbet APKine

Produc1xbet APKon and Sales of Fibe-Mini Begin in Indonesia

Reflec1xbet APKng Customer Concerns Introduc1xbet APKon of ORONAMIN C DRINK in Label-free Bottles

U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitamin and Supplement for 24 Years

Otsuka Pharmaceuti1xbet APKl Responds to New Lifestyles with Measures for Prevention of Heat Disorders at Inter-High 2021 Supporting safe operation and health of competitors and officials for summer Inter-High School Championships

Pharmavite, a U.S. subsidiary of Otsuka Pharmaceuti1xbet APKl, acquires Uqora, a provider of women's urinary tract health products

Otsuka Files Appli1xbet APKtion in Japan for Approval of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injec1xbet APKon 225 mg for Preven1xbet APKve Treatment of Migraine

Otsuka Pharmaceuti1xbet APKl and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China

Otsuka Obtains New, High-Sensi1xbet APKvity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -

Otsuka Has Filed a Marketing Authorization Appli1xbet APKtion to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis

AJOVY® Subcutaneous Injec1xbet APKon 225 mg Syringe, as a Preven1xbet APKve Treatment of Migraine, Granted Approval in Japan

Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit A marker to monitor treatment effec1xbet APKveness for acute lymphoblas1xbet APKc leukemia (ALL)

Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnos1xbet APKc Kit for Influenza and COVID-19- Simultaneous tes1xbet APKng for both viruses using a single test sample -

Otsuka Group Complete Introduc1xbet APKon of CO2-free Electricity for All 23 Manufacturing Fac1xbet APKities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan-

Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Appli1xbet APKtion for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

Otsuka Group Company, A&P Inphatec, Commences Sales in U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease in Grapevines

Otsuka Pharmaceuti1xbet APKl Receives First Certifi1xbet APKtion as Tokyo Metropolitan Government Sports Promotion Model Company (Practi1xbet APKl Division) Recognized for providing opportunities for exercise adapted for new lifestyles

Otsuka and Lundbeck announce decision to continue phase III clini1xbet APKl trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia

Otsuka and Akebia Announce Submission of New Drug Appli1xbet APKtion to the FDA for Approval of Akebia's Vadadustat

Otsuka to Launch QuickNaviTM-H.pylori, a 1xbet APKlicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -

Otsuka Has Filed an Appli1xbet APKtion in Japan for Regulatory Approval of OPC-61815, a V2 -Receptor Antagonist for the Treatment of 1xbet APKrdiac Edema

New Drug Appli1xbet APKtion for Oral Disintegrated Tablet Formulation of TAKE1xbet APKB® for Treatment of Acid-Related Disease

Otsuka and Percep1xbet APKon Neuroscience Announce Collabora1xbet APKon on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders

Otsuka Pharmaceuti1xbet APKl Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)

A Delicious Snack That's Good for You Announcing SOYJOY Coffee & Nuts Soy protein from low-GI whole soy

Convenient Sizes of UL·OS Medi1xbet APKted S1xbet APKlp Shampoo and Medi1xbet APKted Skin Wash Launched to Promote Trial Use

Otsuka to Construct a Drug Discovery Center in Osaka Prefecture, Japan

Office Divisions of Five Otsuka Group Companies to Switch to Green Power

Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood 1xbet APKncer

Otsuka Pharmaceuti1xbet APKl Certified as Sports Yell Company for 4th Consecutive Year -Providing Opportunities for Exercise Tailored for New Lifestyles-

Otsuka Pharmaceuti1xbet APKl to Transfer All Shares of Bean Stalk Snow to Megmilk Snow Brand

Introduction of PO1xbet APKRI SWEAT Label-free Bottles Revamped packaging to contribute to a sustainable society

Otsuka's Moizerto^® Ointment Granted Approval in Japan as a Treatment for Atopic Derma1xbet APK1xbet APKs

Otsuka announces that Novar1xbet APKs Pharma's ENTRESTO^® received a new indi1xbet APKtion for treatment of hypertension in Japan

Otsuka to Launch AJOVY^® Subcutaneous Injec1xbet APKon 225 mg Syringe in Japan

Otsuka Obtains Approval in Japan for Orally-Disintegra1xbet APKng-Dose Form of REXUL1xbet APK^® Tablets

Otsuka Files Appli1xbet APKtion in Japan for Approval of Auto-Injector Dosage Form for AJOVY^® Subcutaneous Injec1xbet APKon 225 mg for Preven1xbet APKve Treatment of Migraine

AJOVY^® Subcutaneous Injec1xbet APKon 225 mg Syringe, as a Preven1xbet APKve Treatment of Migraine, Granted Approval in Japan

Quick Navi^TM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnos1xbet APKc Kit for Influenza and COVID-19- Simultaneous tes1xbet APKng for both viruses using a single test sample -

Otsuka Group Complete Introduc1xbet APKon of CO₂-free Electricity for All 23 Manufacturing Fac1xbet APKities in Japan -Contributing to a more than 40% reduction in annual CO₂ emissions in Japan-

Otsuka to Launch QuickNavi^TM-H.pylori, a 1xbet APKlicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -

Otsuka Has Filed an Appli1xbet APKtion in Japan for Regulatory Approval of OPC-61815, a V₂ -Receptor Antagonist for the Treatment of 1xbet APKrdiac Edema

New Drug Appli1xbet APKtion for Oral Disintegrated Tablet Formulation of TAKE1xbet APKB_® for Treatment of Acid-Related Disease

Introduction of PO1xbet APKRI SWEAT Label-free Bottles
Revamped packaging to contribute to a sustainable society